Methodology inspired by publicly taught biotech catalyst frameworks; all text is an original paraphrase.
Defaults
| Parameter |
Default Value |
Rationale |
| forward_window_quarters |
4 |
Standard catalyst window; extend to 8 on request |
| include_superseded |
false |
Active-only events by default; supersede chains on request |
| exclusivity_tracking |
true |
Orange Book and 180-day exclusivity state attached to launch-relevant events |
| holiday_labeling |
true |
Holiday-shifted weeks flagged on every calendar row |
| horizon_days |
180 |
Default for get_upcoming_pdufa horizon |
Preflight
Run canonical pre-flight per contracts/preflight.md. Include the X-Agentii-Trace header on every tool call per contracts/x-agentii-trace-header.md — carry the _run_id from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via search_companies before catalyst queries.
Triggers
- "When is the PDUFA date for [drug/ticker]?"
- "What AdCom meetings are coming up for [ticker]?"
- "Has [drug]'s sNDA/sBLA label expansion been approved?"
- "Which biosimilars have interchangeability designation, and when does 180-day exclusivity run?"
- "What is [drug]'s Orange Book patent and exclusivity state?"
- "How is [ticker]'s CRL remediation timeline shaping up?"
- "Build a PDUFA/AdCom calendar for my pharma watchlist."
- "Evaluate the approval odds for [drug] ahead of its AdCom."
- "What label expansions are pending for [ticker] this year?"
- "Which medicine decisions land this quarter?"
- "How do biosimilar launches erode the reference product's share?"
- "Which catalysts overlap with [ticker]'s earnings date?"
Production Grounding
- CDER mechanics: NDA/BLA review tracks, PDUFA target dates, priority review, breakthrough designation, accelerated approval, CRL deficiency classes and the remediation reset, AdCom vote patterns.
- Label expansions (sNDA/sBLA) are the commercial catalysts beyond first approval; Orange Book patent and exclusivity state sets the generic or biosimilar entry window.
- Biosimilar timeline note: interchangeability plus 180-day exclusivity for the first interchangeable delays competing entry — and approval is not launch; commercial timing follows exclusivity expiry and patent-settlement terms.
- Holiday-week labeling discipline: comps across holiday-shifted weeks are noisy; every calendar row carries its caveat, and holiday weeks are labeled explicitly.
- Apply AdCom-style scrutiny axes when framing outcome odds; never fabricate dates, votes, or outcomes — annotate coverage gaps instead (per
references/knowledge-frameworks.md).
Data Source Priority
- Structured catalyst data:
get_upcoming_pdufa / get_pdufa_decision (pipeline.fda_calendar_event).
- AdCom and approval history:
search_adcom_meetings / get_adcom_meeting; search_fda_approvals / get_fda_approval.
- Company and filing context:
get_company_profile, search_documents, search_sec_filings; briefing docs via list_sources(source_type=adcom_briefing) + read_source_outline/read_source_pages with meeting slugs.
- Historical grounding:
search_investment_cases (event_type=adcom_vote/pdufa_decision/crl/approval), search_by_analogue, search_investment_strategies (sectors=med).
- Earnings overlap:
search_earnings_calendar / list_upcoming_earnings.
Methodology
Retrieval Scope
unstructured_document_search
Retrieval Strategy
- Resolve ticker(s) via
search_companies; note primary drug/application names.
- Pull active PDUFA events (
get_upcoming_pdufa, horizon_days=default); layer AdCom meetings and earnings dates.
- Per event: decision history (
get_pdufa_decision by drug/application), approval record (get_fda_approval), label and Orange Book state.
- For AdCom events, retrieve briefing documents via
list_sources + read_source_outline/read_source_pages using meeting slugs; apply scrutiny axes.
- Ground the play in knowledge:
search_investment_cases / search_by_analogue with med filters; cite /v/ records.
Temporal Scope
See frontmatter temporal_scope block. Exclusivity windows may require looking back up to 8 quarters when requested.
Tool Allowlist
See frontmatter allowed_tools.
Protocol
- Ticker resolution
- Catalyst enumeration (PDUFA / AdCom / label expansion / exclusivity events)
- Per-event outcome framing (scrutiny axes + decision history)
- Historical analogue retrieval
- Calendar synthesis + exclusivity and risk flags
Modes
- Watchlist (default, multi-ticker): one dated calendar with per-ticker sections, sorted by date.
- Single ticker deep-dive: full event timeline, per-event probability framing, label and exclusivity state.
- Event type: restrict to PDUFA / AdCom / label expansion / biosimilar milestones on request.
- Exclusivity scan: Orange Book and 180-day windows as the launch-timing lens.
Tool Fallbacks
| Failure |
Fallback |
| get_upcoming_pdufa empty |
Search filings (search_documents keyword PDUFA) + search_sec_filings 8-Ks; annotate coverage_gap |
| AdCom briefing path 404 |
search_documents with source_institution filter; degrade to calendar metadata |
| Knowledge tools empty |
Proceed with structured data only; annotate knowledge coverage_gap |
| Orange Book state unknown |
Flag exclusivity window unavailable; never infer expiry dates |
Output File
{ticker}/{YYYY-MM-DD_HHMM}_fda-catalyst-medicines_{affix}.md (watchlist: watchlist/{YYYY-MM-DD_HHMM}_fda-catalyst-medicines-calendar_{affix}.md)
Output Structure
- Executive Summary — highest-impact CDER-track catalysts in the window, 2-3 sentences
- Catalyst Calendar — dated table: date, ticker, event type, drug, application, holiday-week flag, expected-impact framing
- Per-Event Analysis — scrutiny-axes assessment (safety/statistics/subgroups/benefit-risk) + decision history
- Label & Exclusivity State — sNDA/sBLA status, Orange Book state, 180-day windows, biosimilar entry timing
- Historical Analogues — matched cases with /v/ citations and quantified outcomes
- Risk Assessment & Coverage Gaps — binary-risk sizing, overlap clusters, unverified or missing data
Error Handling
| Error |
Fallback |
| No PDUFA rows |
Fall back to earnings + AdCom + label events; annotate coverage_gap — never fabricate dates |
| Superseded dates |
Active-only by default; expose supersede chain via include_superseded=true |
| Ticker not in med universe |
Resolve via CIK/drug-universe match; surface the classification gap |
Memory Load
See contracts/memory-load.md.
Snapshot
See contracts/snapshot-synthesis.md.
Final Summary (TUI)
Include ### Key Citations block with 0-10 clickable /v/ URLs.
References
contracts/citation-and-memory.md
contracts/output-frontmatter-schema.md
contracts/memory-load.md
contracts/snapshot-synthesis.md
contracts/preflight.md
references/knowledge-frameworks.md
1---2name: fda-catalyst-medicines3description: "CDER-track catalyst analysis for medicines: PDUFA target dates, AdCom votes, sNDA/sBLA label expansions, biosimilar interchangeability and 180-day exclusivity, Orange Book state, and CRL remediation timelines — enumerated, verified, and sized per event for any biotech/pharma ticker or watchlist."4sectors: [med.medicines_biotech, med.medical_devices]5multi_ticker_semantics: basket_v1_16temporal_scope:7 default_quarters: 48 max_quarters: 89 description: "Forward catalyst window default 4 quarters; up to 8 for long-horizon exclusivity and remediation mapping."10allowed_tools:11 - get_upcoming_pdufa12 - get_pdufa_decision13 - search_adcom_meetings14 - get_adcom_meeting15 - search_fda_approvals16 - get_fda_approval17 - search_companies18 - get_company_profile19 - search_documents20 - search_sec_filings21 - list_sources22 - read_source_outline23 - read_source_pages24 - search_earnings_calendar25 - list_upcoming_earnings26 - search_investment_cases27 - get_investment_case28 - search_investment_strategies29 - get_investment_strategy30 - search_by_analogue31 - search_knowledge_entries32 - get_knowledge_entry33retrieval_scope: unstructured_document_search34min_tool_diversity: 335parameter_free: false36metadata:37 source: https://skillmd.com/skills/agentii-ai/fda-catalyst-medicines38---3940> Methodology inspired by publicly taught biotech catalyst frameworks; all text is an original paraphrase.4142## Defaults4344| Parameter | Default Value | Rationale |45|-----------|---------------|-----------|46| forward_window_quarters | 4 | Standard catalyst window; extend to 8 on request |47| include_superseded | false | Active-only events by default; supersede chains on request |48| exclusivity_tracking | true | Orange Book and 180-day exclusivity state attached to launch-relevant events |49| holiday_labeling | true | Holiday-shifted weeks flagged on every calendar row |50| horizon_days | 180 | Default for get_upcoming_pdufa horizon |5152## Preflight5354Run canonical pre-flight per `contracts/preflight.md`. Include the `X-Agentii-Trace` header on every tool call per `contracts/x-agentii-trace-header.md` — carry the `_run_id` from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via `search_companies` before catalyst queries.5556## Triggers5758- "When is the PDUFA date for [drug/ticker]?"59- "What AdCom meetings are coming up for [ticker]?"60- "Has [drug]'s sNDA/sBLA label expansion been approved?"61- "Which biosimilars have interchangeability designation, and when does 180-day exclusivity run?"62- "What is [drug]'s Orange Book patent and exclusivity state?"63- "How is [ticker]'s CRL remediation timeline shaping up?"64- "Build a PDUFA/AdCom calendar for my pharma watchlist."65- "Evaluate the approval odds for [drug] ahead of its AdCom."66- "What label expansions are pending for [ticker] this year?"67- "Which medicine decisions land this quarter?"68- "How do biosimilar launches erode the reference product's share?"69- "Which catalysts overlap with [ticker]'s earnings date?"7071## Production Grounding7273- CDER mechanics: NDA/BLA review tracks, PDUFA target dates, priority review, breakthrough designation, accelerated approval, CRL deficiency classes and the remediation reset, AdCom vote patterns.74- Label expansions (sNDA/sBLA) are the commercial catalysts beyond first approval; Orange Book patent and exclusivity state sets the generic or biosimilar entry window.75- Biosimilar timeline note: interchangeability plus 180-day exclusivity for the first interchangeable delays competing entry — and approval is not launch; commercial timing follows exclusivity expiry and patent-settlement terms.76- Holiday-week labeling discipline: comps across holiday-shifted weeks are noisy; every calendar row carries its caveat, and holiday weeks are labeled explicitly.77- Apply AdCom-style scrutiny axes when framing outcome odds; never fabricate dates, votes, or outcomes — annotate coverage gaps instead (per `references/knowledge-frameworks.md`).7879## Data Source Priority80811. Structured catalyst data: `get_upcoming_pdufa` / `get_pdufa_decision` (pipeline.fda_calendar_event).822. AdCom and approval history: `search_adcom_meetings` / `get_adcom_meeting`; `search_fda_approvals` / `get_fda_approval`.833. Company and filing context: `get_company_profile`, `search_documents`, `search_sec_filings`; briefing docs via `list_sources(source_type=adcom_briefing)` + `read_source_outline`/`read_source_pages` with meeting slugs.844. Historical grounding: `search_investment_cases` (event_type=adcom_vote/pdufa_decision/crl/approval), `search_by_analogue`, `search_investment_strategies` (sectors=med).855. Earnings overlap: `search_earnings_calendar` / `list_upcoming_earnings`.8687## Methodology8889### Retrieval Scope90unstructured_document_search9192### Retrieval Strategy931. Resolve ticker(s) via `search_companies`; note primary drug/application names.942. Pull active PDUFA events (`get_upcoming_pdufa`, horizon_days=default); layer AdCom meetings and earnings dates.953. Per event: decision history (`get_pdufa_decision` by drug/application), approval record (`get_fda_approval`), label and Orange Book state.964. For AdCom events, retrieve briefing documents via `list_sources` + `read_source_outline`/`read_source_pages` using meeting slugs; apply scrutiny axes.975. Ground the play in knowledge: `search_investment_cases` / `search_by_analogue` with med filters; cite /v/ records.9899### Temporal Scope100See frontmatter temporal_scope block. Exclusivity windows may require looking back up to 8 quarters when requested.101102### Tool Allowlist103See frontmatter allowed_tools.104105### Protocol1061. Ticker resolution1072. Catalyst enumeration (PDUFA / AdCom / label expansion / exclusivity events)1083. Per-event outcome framing (scrutiny axes + decision history)1094. Historical analogue retrieval1105. Calendar synthesis + exclusivity and risk flags111112## Modes113114- **Watchlist** (default, multi-ticker): one dated calendar with per-ticker sections, sorted by date.115- **Single ticker deep-dive**: full event timeline, per-event probability framing, label and exclusivity state.116- **Event type**: restrict to PDUFA / AdCom / label expansion / biosimilar milestones on request.117- **Exclusivity scan**: Orange Book and 180-day windows as the launch-timing lens.118119## Tool Fallbacks120121| Failure | Fallback |122|---------|----------|123| get_upcoming_pdufa empty | Search filings (`search_documents` keyword PDUFA) + `search_sec_filings` 8-Ks; annotate coverage_gap |124| AdCom briefing path 404 | `search_documents` with source_institution filter; degrade to calendar metadata |125| Knowledge tools empty | Proceed with structured data only; annotate knowledge coverage_gap |126| Orange Book state unknown | Flag exclusivity window unavailable; never infer expiry dates |127128## Output File129130`{ticker}/{YYYY-MM-DD_HHMM}_fda-catalyst-medicines_{affix}.md` (watchlist: `watchlist/{YYYY-MM-DD_HHMM}_fda-catalyst-medicines-calendar_{affix}.md`)131132## Output Structure1331341. **Executive Summary** — highest-impact CDER-track catalysts in the window, 2-3 sentences1352. **Catalyst Calendar** — dated table: date, ticker, event type, drug, application, holiday-week flag, expected-impact framing1363. **Per-Event Analysis** — scrutiny-axes assessment (safety/statistics/subgroups/benefit-risk) + decision history1374. **Label & Exclusivity State** — sNDA/sBLA status, Orange Book state, 180-day windows, biosimilar entry timing1385. **Historical Analogues** — matched cases with /v/ citations and quantified outcomes1396. **Risk Assessment & Coverage Gaps** — binary-risk sizing, overlap clusters, unverified or missing data140141## Error Handling142143| Error | Fallback |144|-------|----------|145| No PDUFA rows | Fall back to earnings + AdCom + label events; annotate `coverage_gap` — never fabricate dates |146| Superseded dates | Active-only by default; expose supersede chain via `include_superseded=true` |147| Ticker not in med universe | Resolve via CIK/drug-universe match; surface the classification gap |148149## Memory Load150151See `contracts/memory-load.md`.152153## Snapshot154155See `contracts/snapshot-synthesis.md`.156157## Final Summary (TUI)158159Include ### Key Citations block with 0-10 clickable /v/ URLs.160161## References162163- `contracts/citation-and-memory.md`164- `contracts/output-frontmatter-schema.md`165- `contracts/memory-load.md`166- `contracts/snapshot-synthesis.md`167- `contracts/preflight.md`168- `references/knowledge-frameworks.md`